Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Leukemia
•
CML
•
Hematology
Do you recommend antimicrobial prophylaxis in patients with CML blast crisis after 7+3 induction while on maintenance TKI awaiting allo transplant?
Related Questions
Is there therapeutic relevance for FLT3-ITD mutation in relapsed APML?
How do you manage persistent cytopenias after FCR chemotherapy for treatment of CLL?
Does treating CLL reduce the risk of non-melanoma skin cancers?
How do you treat patients with T-cell ALL/T-cell lymphoblastic lymphoma who have pre-existing CKD with a CrCl of 30 mL/min or less?
How do you approach neutropenia in patients being treated with obinutuzumab/venetoclax for CLL?
In an elderly transplant ineligible IDH1-mutated patient with AML, who is in remission after 6 cycles of azacitidine and ivosidenib, would you discontinue azacitidine after cycle 6 and continue maintenance ivosidenib until progression/toxicity or continue both azacitidine and ivosidenib?
Do you routinely include bone marrow examination in your initial evaluation of a patient with chronic myeloid leukemia?
What is your approach to management of relapsed/refractory T-cell prolymphocytic leukemia (T-PLL)?
Does ASC4FIRST data justify the use of first-line asciminib for all newly diagnosed CML over other TKIs, considering that post-progression survival data is not yet mature?
Can AMPLIFY data be extrapolated to use of other BTKi's in combination with venetoclax or would you only ever use acalabrutinib/venetoclax in first line?
